EDAP TMS (EDAP) Q1 2026 earnings review
HIFU Adoption Goes Parabolic, But Cash Burn Flashes Red
EDAP delivered a spectacular top-line quarter, driven by a 78% YoY surge in core HIFU revenue. The dark cloud of Medicare Advantage payer pushback that choked U.S. procedure growth early last year has fully dissipated, with procedure volumes accelerating to a massive 53% growth rate. The strategic shift away from legacy businesses is working, pushing gross margins up to 45.7%. However, the cost of this commercial success is steep. Operating expenses outpaced revenue growth, widening the net loss to $9.1M. With cash dwindling to $15.0M against a $5.7M quarterly operating cash burn, the balance sheet contradicts the rosy revenue narrative.
🐂 Bull Case
U.S. procedure volume has completely broken through the Medicare Advantage friction seen in early 2025. Accelerating 53% growth proves that both patient demand and reimbursement pathways are firmly established.
Gross margins expanded 370 basis points YoY as the company intentionally shrinks its lower-margin legacy ESWL business to focus entirely on high-margin robotic HIFU.
🐻 Bear Case
Cash dropped by over $5.4M in a single quarter to just $15.0M. At this burn rate, a dilutive capital raise or heavy debt reliance is imminent.
Despite a massive 78% surge in its core, high-margin business, operating loss widened from $6.3M to $7.4M YoY. Management is spending heavily to fuel this growth, and profitability remains nowhere in sight.
⚖️ Verdict: ⚪
Neutral. The commercial execution and adoption curve for Focal One are flawless, but severe balance sheet constraints and widening losses prevent a higher grade. Investors must brace for potential dilution.
Key Themes
U.S. Procedure Volume Breakout
Accelerating. The most critical leading indicator for EDAP is procedure volume, which drives recurring disposable revenue. Growth skyrocketed to 53% YoY, completely leaving behind the sluggish 4% growth from Q1 2025. This signals that the macro reimbursement environment—specifically Medicare Advantage pre-authorizations—has decisively turned in EDAP's favor.
Sustained Capital Sales Momentum
Stable. The company sold 11 Focal One systems globally, an 83% YoY increase. Demand remains highly durable, continuing the momentum from a record back-half of 2025. Capital sales in key international markets (UK, France, Hungary) demonstrate that adoption is broadening geographically.
Gross Margin Expansion
Accelerating. Gross margin improved from 42.0% to 45.7%. Management is successfully executing a deliberate mix shift, shrinking the non-core ESWL and Distribution segments while aggressively scaling the high-margin HIFU business. Better absorption of fixed costs is also contributing to the margin lift.
Liquidity Crisis Looming
Decelerating. Cash and short-term investments fell sharply from $20.4M at year-end to $15.0M. The company generated a negative operating cash flow of $5.7M for the quarter. While they secured an EIB credit facility in 2025, the underlying cash burn is aggressive and leaves little margin for error.
Operating Leverage is Non-Existent
Reversing. A core premise of the bull thesis is that high-margin recurring revenues will eventually outpace fixed costs. However, SG&A expenses surged 33% YoY to $12.9M. Consequently, despite adding $2.1M in gross profit, the operating loss actually widened to $7.4M. The company is buying its top-line growth at a steep price.
Tariff and Macro Headwinds Remain Unquantified
Stable. In 2025, management flagged a 10-15% tariff impact on goods shipped from France to the U.S. While gross margins improved this quarter, the cost base remains structurally vulnerable to trade policies, as 100% of Focal One assembly occurs in France. This dynamic will require ongoing monitoring.
Clinical Validation Deepens: Salvage Therapy & Endometriosis
Accelerating. The HIFI-2 study results in European Urology Oncology validate Focal One for salvage treatment following failed radiation therapy—a notoriously difficult patient population. Additionally, international capital sales are now explicitly targeting deep infiltrating endometriosis, moving the platform beyond a single-indication tool into a broader women's health and oncology ecosystem.
Other KPIs
Accelerating. OpEx grew 26% YoY, driven almost entirely by SG&A spending ($12.9M). This reflects the aggressive commercial investments required to place systems and support the massive 53% spike in U.S. procedures.
Decelerating. Down 20.5% YoY from $7.8M. This is an intentional sunsetting of the legacy ESWL and distribution segments to free up capital and commercial bandwidth for the robotic HIFU platform.
Guidance
Decelerating. The guidance implies 34% to 45% YoY growth. While strong in absolute terms, this is a deceleration from the massive 78% growth posted in Q1, indicating management expects tougher comparisons and potentially lumpier capital sales in the back half of the year.
Decelerating. Reflects the continued structural wind-down of legacy operations.
Key Questions
Capital Runway Timeline
With only $15.0M in cash and a quarterly operating cash burn of $5.7M, what is the exact timeline and preferred structure for the next capital injection? Is the EIB facility fully drawn?
Path to Profitability
Despite 78% core growth and expanding gross margins, operating losses worsened. At what annualized HIFU revenue run-rate do you expect SG&A to scale and operating leverage to finally turn positive?
Procedure Surge Drivers
U.S. procedures grew 53% YoY. How much of this was a temporary flush of patients previously backlogged by Medicare Advantage pre-authorization delays versus sustained, organic new demand?
Tariff Mitigation
With ongoing uncertainty around global trade, what concrete steps are being taken to mitigate tariff exposure on systems assembled in France and exported to your largest growth market?